Patents by Inventor Luis Barrera
Luis Barrera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11963982Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid.Type: GrantFiled: November 8, 2019Date of Patent: April 23, 2024Assignee: EDITAS MEDICINE, INC.Inventors: Edouard Aupepin De Lamothe-Dreuzy, Jack Heath, Jennifer Leah Gori, Luis Barrera
-
Patent number: 11851690Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.Type: GrantFiled: September 12, 2019Date of Patent: December 26, 2023Assignee: EDITAS MEDICINE, INC.Inventors: Jennifer Leah Gori, Luis A. Barrera, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath
-
Patent number: 11844825Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.Type: GrantFiled: May 7, 2021Date of Patent: December 19, 2023Assignee: Saint Louis UniversityInventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
-
Publication number: 20230340456Abstract: The present disclosure is directed to methods of producing a modified nucleic acid comprising a precise deletion in a target nucleic acid in a cell comprising generating, within the cell, a first single strand break on a first strand of the target nucleic acid and a second single strand break on a second strand of the target nucleic acid, thereby forming a double strand break in the target nucleic acid having a first 3? overhang and a second 3? overhang; processing the first 3? overhang and the second 3? overhang with an exonuclease molecule, thereby deleting the segment of the target nucleic acid that was located between the first single strand break and the second single strand break, and forming a processed double strand break; and allowing the processed double strand break to be repaired by at least one DNA repair pathway, thereby producing the modified nucleic acid comprising the precise deletion in the target nucleic acid in the cell.Type: ApplicationFiled: April 25, 2023Publication date: October 26, 2023Inventors: Anne Helen Bothmer, Cecilia Cotta-Ramusino, Luis A. Barrera
-
Publication number: 20230279373Abstract: The present invention provides novel systems, methods and compositions for making and using a recombinantly engineered novel Cas9 optimized for human cells, for nucleic acid targeting and manipulation. The present invention is based on the discovery of a novel Cas9 species from Lachnospira bacterium that was codon-optimized and recombinantly produced for use in human ceils. In some embodiments, the novel Cas9 can be used in a base editor. In some embodiments, the novel engineered Cas9 is used to treat human diseases.Type: ApplicationFiled: September 9, 2020Publication date: September 7, 2023Inventors: Bernd ZETSCHE, Luis BARRERA
-
Patent number: 11667911Abstract: The present disclosure is directed to methods of producing a modified nucleic acid comprising a precise deletion in a target nucleic acid in a cell comprising generating, within the cell, a first single strand break on a first strand of the target nucleic acid and a second single strand break on a second strand of the target nucleic acid, thereby forming a double strand break in the target nucleic acid having a first 3? overhang and a second 3? overhang; processing the first 3? overhang and the second 3? overhang with an exonuclease molecule, thereby deleting the segment of the target nucleic acid that was located between the first single strand break and the second single strand break, and forming a processed double strand break; and allowing the processed double strand break to be repaired by at least one DNA repair pathway, thereby producing the modified nucleic acid comprising the precise deletion in the target nucleic acid in the cell.Type: GrantFiled: September 23, 2016Date of Patent: June 6, 2023Assignee: Editas Medicine, Inc.Inventors: Anne Helen Bothmer, Cecilia Cotta-Ramusino, Luis A. Barrera
-
Publication number: 20230070861Abstract: The invention features compositions and methods for introducing mutations into the hepatitis B virus (HBV) genome.Type: ApplicationFiled: May 8, 2020Publication date: March 9, 2023Applicant: Beam Therapeutics Inc.Inventors: Elena SMEKALOVA, Michael PACKER, Francine GREGOIRE, Luis BARRERA, Giuseppe CIARAMELLA
-
Patent number: 11529397Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.Type: GrantFiled: January 22, 2018Date of Patent: December 20, 2022Assignee: Saint Louis UniversityInventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
-
Patent number: 11499151Abstract: The present disclosure relates to methods of assessing a sample of guide RNAs (gRNAs).Type: GrantFiled: April 27, 2018Date of Patent: November 15, 2022Assignee: Editas Medicine, Inc.Inventors: Cecilia Fernandez, Georgia Giannoukos, Luis Barrera, Dawn Ciulla, Terence Ta
-
Publication number: 20220313799Abstract: The present invention features compositions and methods for editing a gene associated with Shwachman Diamond Syndrome (SDS) using a programmable nucleobase editor, such that the gene is permissive for transcription and generates a functional gene product (e.g., providing a splice site and/or altering a nonsense mutation).Type: ApplicationFiled: August 28, 2020Publication date: October 6, 2022Applicant: Beam Therapeutics Inc.Inventors: Jason Michael GEHRKE, Luis BARRERA, Angelica MESSANA
-
Publication number: 20210260172Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.Type: ApplicationFiled: May 7, 2021Publication date: August 26, 2021Inventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
-
Publication number: 20200255857Abstract: CRISPR/CAS-related compositions and methods for treatment of beta hemoglobinopathies are disclosed.Type: ApplicationFiled: March 14, 2017Publication date: August 13, 2020Inventors: Jennifer Leah GORI, Luis A. BARRERA
-
Publication number: 20200190513Abstract: The present disclosure relates to methods of assessing a sample of guide RNAs (gRNAs).Type: ApplicationFiled: April 27, 2018Publication date: June 18, 2020Applicant: Editas Medicine, Inc.Inventors: Cecilia FERNANDEZ, Georgia GIANNOUKOS, Luis BARRERA, Dawn CIULLA, Terence TA
-
Publication number: 20200155606Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid.Type: ApplicationFiled: November 8, 2019Publication date: May 21, 2020Applicant: Editas Medicine, Inc.Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, Jennifer LEAH GORI, Luis BARRERA
-
Publication number: 20200157515Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.Type: ApplicationFiled: September 12, 2019Publication date: May 21, 2020Inventors: Jennifer Leah GORI, Luis A. Barrera, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath
-
Publication number: 20190224283Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.Type: ApplicationFiled: January 22, 2018Publication date: July 25, 2019Inventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
-
Publication number: 20180273932Abstract: The present disclosure is directed to methods of producing a modified nucleic acid comprising a precise deletion in a target nucleic acid in a cell comprising generating, within the cell, a first single strand break on a first strand of the target nucleic acid and a second single strand break on a second strand of the target nucleic acid, thereby forming a double strand break in the target nucleic acid having a first 3? overhang and a second 3? overhang; processing the first 3? overhang and the second 3? overhang with an exonuclease molecule, thereby deleting the segment of the target nucleic acid that was located between the first single strand break and the second single strand break, and forming a processed double strand break; and allowing the processed double strand break to be repaired by at least one DNA repair pathway, thereby producing the modified nucleic acid comprising the precise deletion in the target nucleic acid in the cell.Type: ApplicationFiled: September 23, 2016Publication date: September 27, 2018Inventors: Anne Helen Bothmer, Cecilia Cotta-Ramusino, Luis A. Barrera
-
Publication number: 20110311487Abstract: This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.Type: ApplicationFiled: May 20, 2011Publication date: December 22, 2011Applicant: Saint Louis UniversityInventors: Shunji Tomatsu, Adriana M. Montaño-Suarez, Carlos J. Alméciga-Diaz, Luis Barrera
-
Patent number: 7972593Abstract: This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.Type: GrantFiled: July 3, 2009Date of Patent: July 5, 2011Assignee: Saint Louis UniversityInventors: Shunji Tomatsu, Adriana Montaño-Suarez, Carlos J. Alméciga-Diaz, Luis Barrera
-
Publication number: 20100008979Abstract: This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.Type: ApplicationFiled: July 3, 2009Publication date: January 14, 2010Applicant: Saint Louis UniversityInventors: Shunji Tomatsu, Adriana M. Montaño-Suarez, Carlos J. Alméciga-Diaz, Luis Barrera